RPG Life Sciences posts Q2 FY25 revenue Up by 12% YoY
Revenue from operations registered a growth of 12% Y-o-Y at Rs 337.63 crores for H1 FY25
Revenue from operations registered a growth of 12% Y-o-Y at Rs 337.63 crores for H1 FY25
Revenue at Rs 3,623 crore, EBITDA at Rs 718 crore
CMG1A46 is an investigational T cell-engager with potential to deeply deplete uncontrolled B cells present in autoimmune diseases such as lupus
The workshop aimed to equip medicos with the necessary skills & knowledge to leverage AI's transformative power
Revolf's infertility and miscarriage tests are a new technology that uses blood tests to detect neoself-antibodies
Fludrocortisone acetate tablets will be produced at the Group's manufacturing site at Moraiya, Ahmedabad
SIBUR is developing a special grade of polycarbonate compatible with radiation sterilization
WEF recognises company’s Bharuch manufacturing facility as a global manufacturing lighthouse
US$ 800 million senior secured notes, the largest high yield debut USD bond issuance from India in the last 10 years
Subscribe To Our Newsletter & Stay Updated